{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-007532","form_type":"8-K","ticker":"ALXO","cik":"0001810182","company_name":"ALX ONCOLOGY HOLDINGS INC","filed_at":"2025-01-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.972956+00:00","generated_at":"2026-05-27T20:53:30.118876+00:00","sec_items":["5.02","7.01","8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ALX Oncology appoints Harish Shantharam as CFO and adds Klencke, Takimoto to board","bullets":["Harish Shantharam named CFO effective Jan 21, 2025; base salary $490k, target bonus 40%, option for 600k shares.","Barbara Klencke, M.D. and Chris Takimoto, M.D., Ph.D. appointed to Board effective Jan 18, 2025; each receives initial option for 40,400 shares.","Shantharam previously CFO of CymaBay ($4.3B Gilead acquisition); held finance roles at Gilead and Amgen.","Klencke serves on boards of Xencor, TScan, Immune-Onc; Takimoto is CMO at START Center, former CMO at Forty Seven ($4.9B Gilead acquisition).","Board expanded to 6 members; new committee assignments: Klencke on Audit/R&D, Takimoto on Compensation/R&D."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-007532","json":"https://secwatch.observer/filing/0000950170-25-007532.json","markdown":"https://secwatch.observer/filing/0000950170-25-007532.md","text":"https://secwatch.observer/filing/0000950170-25-007532.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810182/000095017025007532/0000950170-25-007532-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810182/000095017025007532/alxo-20250116.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T20:53:30.118876+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"255e2e0755","claim":"Barbara Klencke was appointed as Director at ALX ONCOLOGY HOLDINGS INC.","evidence_excerpt":"Effective January 18, 2025, the Board appointed Barbara Klencke, M.D. to serve as a Class II director of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810182/000095017025007532/0000950170-25-007532-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"25bac7d6c1","claim":"Shelly Pinto resigned as Interim Chief Financial Officer at ALX ONCOLOGY HOLDINGS INC.","evidence_excerpt":"Ms. Pinto resigned as the interim Chief Financial Officer effective as of the same date and will remain the Company’s Senior Vice President, Finance and Chief Accounting Officer and the principal accounting officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810182/000095017025007532/0000950170-25-007532-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Interim Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"b866a14e3f","claim":"Chris Takimoto was appointed as Director at ALX ONCOLOGY HOLDINGS INC.","evidence_excerpt":"and Chris Takimoto, M.D., Ph.D., F.A.C.P., to serve as a Class III director of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810182/000095017025007532/0000950170-25-007532-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"f69cfedc02","claim":"Harish Shantharam was appointed as Chief Financial Officer at ALX ONCOLOGY HOLDINGS INC.","evidence_excerpt":"Effective January 21, 2025, the Board of Directors (the “Board”) of ALX Oncology Holdings Inc. (the “Company”) appointed Harish Shantharam to the office of Chief Financial Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810182/000095017025007532/0000950170-25-007532-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}